STOCK TITAN

Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management

Sarepta Therapeutics (NASDAQ:SRPT) has appointed Deirdre P. Connelly to its Board of Directors, expanding the board to nine members, with eight being independent. Connelly brings over 30 years of pharmaceutical industry experience, having served as president of North America Pharmaceuticals for GlaxoSmithKline and president of U.S. Pharmaceutical Operations at Eli Lilly. Her extensive background includes executive roles in human resources and pharmaceutical operations.

Currently, Connelly serves on the boards of Macy's and Lincoln Financial Group, and is the Chairperson of the Board at Genmab A/B. This appointment aligns with Sarepta's strategy to deliver transformative therapies for rare diseases, leveraging Connelly's seasoned leadership and industry expertise.

Sarepta Therapeutics (NASDAQ:SRPT) ha nominato Deirdre P. Connelly nel suo Consiglio di Amministrazione, ampliando il consiglio a nove membri, di cui otto sono indipendenti. Connelly porta con sé oltre 30 anni di esperienza nell'industria farmaceutica, avendo ricoperto il ruolo di presidente della divisione farmaceutica per il Nord America di GlaxoSmithKline e presidente delle operazioni farmaceutiche negli Stati Uniti di Eli Lilly. Il suo ampio background include ruoli dirigenziali nelle risorse umane e nelle operazioni farmaceutiche.

Attualmente, Connelly è membro dei consigli di Macy's e Lincoln Financial Group ed è la Presidente del Consiglio di Genmab A/B. Questa nomina si allinea con la strategia di Sarepta di fornire terapie trasformative per malattie rare, sfruttando la leadership esperta e le competenze del settore di Connelly.

Sarepta Therapeutics (NASDAQ:SRPT) ha nombrado a Deirdre P. Connelly en su Junta Directiva, ampliando la junta a nueve miembros, de los cuales ocho son independientes. Connelly aporta más de 30 años de experiencia en la industria farmacéutica, habiendo sido presidenta de Farmacéuticos de América del Norte en GlaxoSmithKline y presidenta de Operaciones Farmacéuticas en EE. UU. en Eli Lilly. Su amplia experiencia incluye roles ejecutivos en recursos humanos y operaciones farmacéuticas.

Actualmente, Connelly forma parte de las juntas de Macy's y Lincoln Financial Group, y es la Presidenta de la Junta en Genmab A/B. Este nombramiento está alineado con la estrategia de Sarepta para ofrecer terapias transformadoras para enfermedades raras, aprovechando el liderazgo experimentado y la pericia de la industria de Connelly.

Sarepta Therapeutics (NASDAQ:SRPT)는 Deirdre P. Connelly를 이사회에 임명하여 이사회 멤버를 아홉 명으로 확장했으며, 그 중 여덟 명은 독립적입니다. Connelly는 GlaxoSmithKline의 북미 제약 부문 사장 및 Eli Lilly의 미국 제약 운영 사장을 역임하며 30년 이상의 제약 산업 경험을 가지고 있습니다. 그녀의 폭넓은 배경에는 인사 및 제약 운영 분야의 임원 역할이 포함되어 있습니다.

현재 Connelly는 Macy's 및 Lincoln Financial Group의 이사로 활동하고 있으며, Genmab A/B의 이사회 의장입니다. 이 임명은 Connelly의 풍부한 리더십과 산업 전문성을 활용하여 희귀 질병에 대한 혁신적인 치료법을 제공하려는 Sarepta의 전략과 일치합니다.

Sarepta Therapeutics (NASDAQ:SRPT) a nommé Deirdre P. Connelly au sein de son Conseil d'Administration, élargissant ainsi le conseil à neuf membres, dont huit sont indépendants. Connelly apporte plus de 30 ans d'expérience dans l'industrie pharmaceutique, ayant été présidente de la branche pharmaceutique pour l'Amérique du Nord chez GlaxoSmithKline et présidente des opérations pharmaceutiques aux États-Unis chez Eli Lilly. Son vaste parcours comprend des postes de direction dans les ressources humaines et les opérations pharmaceutiques.

Actuellement, Connelly siège au conseil d'administration de Macy's et de Lincoln Financial Group, et est la présidente du conseil d'administration de Genmab A/B. Cette nomination est conforme à la stratégie de Sarepta visant à fournir des thérapies transformantes pour les maladies rares, tirant parti du leadership aguerri et de l'expertise de Connelly dans l'industrie.

Sarepta Therapeutics (NASDAQ:SRPT) hat Deirdre P. Connelly in seinen Aufsichtsrat berufen, wodurch der Vorstand auf neun Mitglieder erweitert wird, von denen acht unabhängig sind. Connelly bringt über 30 Jahre Erfahrung in der Pharmaindustrie mit, nachdem sie Präsidentin für Nordamerika bei GlaxoSmithKline und Präsidentin der Pharmabetriebe in den USA bei Eli Lilly war. Ihr umfangreicher Hintergrund umfasst Führungspositionen im Personalwesen und in den Pharmaoperationen.

Derzeit ist Connelly Mitglied in den Aufsichtsräten von Macy's und Lincoln Financial Group und Vorsitzende des Aufsichtsrats von Genmab A/B. Diese Ernennung steht im Einklang mit der Strategie von Sarepta, transformative Therapien für seltene Krankheiten anzubieten und dabei Connellys erfahrene Führung und Branchenkenntnis zu nutzen.

Positive
  • Addition of an experienced pharmaceutical executive to the Board of Directors
  • Expansion of the Board to nine members, with eight being independent
  • Potential for fresh perspectives and insights from Connelly's 30+ years of industry experience
  • Strengthening of leadership team to support company growth and strategy execution
Negative
  • None.

- Veteran biopharmaceutical executive from GSK and Eli Lilly brings more than 30 years of experience to Sarepta’s Board

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Deirdre P. Connelly to its Board of Directors. Ms. Connelly is a well-regarded executive with more than 30 years of experience in the pharmaceutical industry. Following Connelly’s appointment, Sarepta’s Board will comprise nine directors, eight of whom are independent.

“Ms. Connelly is a seasoned board leader with extensive operating experience in biopharma and we’re pleased to welcome her to the Sarepta Board of Directors as we work to deliver on our strategy to bring transformative therapies to patients with rare diseases,” said M. Kathleen Behrens, Ph.D., Chairperson of Sarepta’s Board of Directors.

“It’s an honor to join Sarepta’s Board and contribute to the next phase of the Company’s growth,” said Ms. Connelly. “I’m inspired by Sarepta’s science-driven mission and look forward to working alongside the Sarepta team, who represent the best and brightest of our industry, and to building upon their extraordinary accomplishments to bring life-changing therapies to patients.”

Connelly retired as president, North America Pharmaceuticals for GlaxoSmithKline (GSK) in 2015, a role she had held since 2009. Prior to joining GSK, she was with Eli Lilly and Company, where she served as president, U.S. Pharmaceutical Operations from 2005 to 2009. During her 26-year career with Eli Lilly, she held a variety of executive positions, including senior vice president of human resources for the corporation, as well as vice president of human resources for pharmaceutical operations. Connelly currently serves on the board of directors at Macy’s Corporation and Lincoln Financial Group, in addition to serving as the Chairperson of the Board at Genmab A/B.

Born in San Juan, Puerto Rico, Connelly earned a bachelor’s degree in economics and business management from Lycoming College and is a graduate of Harvard University's Advanced Management Program.

About Sarepta Therapeutics

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Forward-Looking Statements

This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding Sarepta’s mission and potential to bring life-changing therapies to patients and the potential benefits of the addition of Deirdre Connelly to Sarepta’s Board.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s control. Known risk factors include, among others: Sarepta may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, clinical development plans, and bringing its products to U.S. and ex-U.S. markets for various reasons including possible limitations of Company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover Sarepta’s product candidates; and those risks identified under the heading “Risk Factors” in Sarepta’s most recent Annual Report on Form 10-K for the year ended December 31, 2023, and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Company’s business, results of operations and the trading price of Sarepta’s common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law.

Investor Contact:

Ian Estepan, 617-274-4052

iestepan@sarepta.com

Media Contact:

Tracy Sorrentino, 617-301-8566

tsorrentino@sarepta.com

Source: Sarepta Therapeutics, Inc.

FAQ

Who is Deirdre Connelly and why was she appointed to Sarepta Therapeutics' Board?

Deirdre Connelly is a veteran biopharmaceutical executive with over 30 years of experience, formerly with GSK and Eli Lilly. She was appointed to Sarepta Therapeutics' Board to contribute her extensive industry knowledge and leadership experience to support the company's growth and strategy in developing therapies for rare diseases.

How many members are now on Sarepta Therapeutics' (SRPT) Board of Directors?

Following Deirdre Connelly's appointment, Sarepta Therapeutics' (SRPT) Board of Directors now comprises nine members, eight of whom are independent.

What is Deirdre Connelly's background in the pharmaceutical industry?

Deirdre Connelly has over 30 years of experience in the pharmaceutical industry. She served as president of North America Pharmaceuticals for GlaxoSmithKline from 2009 to 2015 and as president of U.S. Pharmaceutical Operations at Eli Lilly from 2005 to 2009. She also held various executive positions at Eli Lilly, including senior vice president of human resources.

What other board positions does Deirdre Connelly currently hold?

Deirdre Connelly currently serves on the board of directors at Macy's and Lincoln Financial Group. She is also the Chairperson of the Board at Genmab A/B.

Sarepta Therapeutics,, Inc.

NASDAQ:SRPT

SRPT Rankings

SRPT Latest News

SRPT Stock Data

10.54B
90.39M
4.37%
92.02%
5.86%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE